The aim of this report was to study the effect of sildena®l, a speci®c type-5 phosphodiesterase inhibitor, on human sperm motility, viability, membrane integrity and sperm penetration assay.
Introduction
Phosphodiesterases (PDE) are a class of intracellular enzymes that break down intracellular cyclic 3
H 5 Hguanosine monophosphate (cGMP) and cyclic 3
H 5 Hadenosine monophosphate (cAMP). 1 As many as nine types of PDE enzymes have been characterized in the human body. 2, 3 Sildena®l, a widely prescribed oral medication for the treatment of male erectile dysfunction, is a selective and highly potent inhibitor of the type-5 cGMP-speci®c phosphodiesterase. 4 Type-5 PDE isozyme is predominantly expressed in the penile corpus cavernosum, however it has been localized in various other tissues, such as brain, lung, kidney and placenta. 5 Although little is known about the physiological role of PDE and its isoforms in human spermatozoa, its inhibition has been reported to stimulate sperm motility, suggesting an association between the levels of cytosolic nucleotides and sperm motion. 2, 6 Human spermatozoa has been shown to have two distinct PDE isoforms (PDE 1 and PDE 4). Speci®c inhibition of these isoforms by rolipram and methylxanthine has been shown to improve sperm motility and acrosome reaction. 2, 7 Since its introduction to clinical practice in 1998, sildena®l (Viagra, P®zer, New York, NY) has become a highly prescribed drug for the treatment of male sexual dysfunction. Its use among younger men for sexual enhancement and women of childbearing age, however, is undocumented. Sildena®l, when administered at 100 mg oral dose (the maximal therapeutic dose) can cause minor inhibition of PDE 1 and PDE 6, which is related to its transient side effects. 8 It's likely that at this concentration it may improve sperm motility by blocking PDE 1 or some other as yet uncharacterized PDE isoform present in sperm cells.
The aim of this study was to analyze the effect of sildena®l on the motility, viability, membrane integrity, and functional capacity of human spermatozoa. Sperm of normal quality from healthy donors and sperm from clinically infertile men were studied after incubation with varying doses of sildena®l and controls. Pentoxifylline (an agent which improves sperm motion and capacitation) was utilized as a positive control group in this study, and Ham's F-10 medium was used as a reagent control. 6 
Materials and methods

Sperm preparation
Semen samples from normal donors (n 6) and infertile patients (n 6) attending our andrology clinic were obtained by masturbation into a sterile cup after at least 2 days of abstinence. Clinical infertility was de®ned as per World Health Organization criteria. 9 The patients chosen for this study exhibited sperm motility which was about 30% with`2 grade progression, and sperm viability less than 50% as shown by hypo-osmotic swelling test and vital staining procedures. Samples were allowed to liquify for 30 min at room temperature, washed using a single Percoll gradient (80%) (Sigma Chemical Company, St Louis, MO) to remove all cellular debris as well as seminal plasma components, and resuspended in Ham's F-10 medium containing 0.4% albumin. Separate aliquots (0.1 ml, each containing about 10610 6 spermatozoa) were incubated in the absence or presence of sildena®l (125, 250 and 750 ngaml; Stanford Research Institute, Menlo Park, CA), pentoxyfylline (3 mM; Sigma Chemical Company, St Louis, MO) as a positive control, and Ham's F-10 medium as a reagent control. 6 
Sperm motion analysis
An aliquot (7 ml) was used to assess sperm motion at 1 and 3 h of incubation with the various agents. Videomicrography recording was carried out at 206phase objective for evaluating computer-assisted sperm motion analysis parameters (straight line velocity, curvilinear velocity, linearity and amplitude of lateral head displacement) using the Cell-TrakaSemen Analysis System (Motion Analysis Corp., Santa Rosa, CA) as described earlier. 6 In addition to these motion analyses, the percentage of motile sperm and the grade of motility were assessed manually by a single observer at the indicated time intervals.
Assessment of sperm viability and membrane integrity
Sperm viability was assessed in an aliquot (7 ml) by supravital staining with eosin Y (5%). Nigrosin (10%) was used as a contrasting stain. A total of 200 spermatozoa were counted, and the percentage of viable heads (unstained) calculated as per the WHO manual (1999). The hypo-osmotic swelling test (HOST) was used to evaluate the membrane integrity of sperm by observing the ability of sperm tails to undergo swelling as per the WHO protocol. Sperm tails with functional membranes curl and swell on incubation in a hypo-osmotic medium, but those lacking an intact membrane do not. 9, 10 Using a 206 phase objective, the sperm whose tails were curled or swollen were counted as HOST-positive.
Assessment of sperm fertilization potential by hamster egg sperm penetration assay (SPA)
To test whether incubation of sperm from normal donors or infertile patients with sildena®l (125, 250 and 750 ngaml), pentoxifylline (3 mM), and Ham's F-10 has any effect on their ovum-penetration capacity, SPA was performed using hamster ova (Baylor College of Medicine, Houston, TX) as described by Johnson et al. 11 Sperm from normal donors and infertile patients were incubated for 3 h with sildena®l (125, 250 and 750 ngaml) and pentoxifylline (3 mM). Sperm were processed by swim-up procedure before the SPA was performed. These samples were capacitated at 37 C in a humidi®ed CO 2 incubator (5% CO 2 ) for 24 h before an aliquot (0.1 ml) was incubated with zona-free eggs (15 ± 20 ovaeasample) and overlaid with paraf®n oil. After 3 h incubation, the ovae were removed, washed twice, and observed under a microscope. Intact ovae with and without penetrated sperm were counted and scored using the sperm capacitation index (SCI), which is de®ned as the total number of sperm penetrations per ovum. An SCI of less than 5 indicates a statistically lower probability of penetration occurring in human ova; an SCI of 0 is considered functionally impaired. 11 
Statistical analysis
Changes in sperm motion and function parameters after treatment with sildena®l were assessed at various time intervals. The data were compared with baseline (t 0 h) and the controls. Multiple group comparisons were made using two-way analysis of variance (ANOVA), and a value of P`0.05 was considered signi®cant.
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Results
Effect of sildena®l on sperm motility
No signi®cant change in motility was observed at 0, 1 and 3 h after incubation of spermatozoa from normal donors or infertile patients with sildena®l (125, 250 and 750 ngaml) when compared to Ham's control (Figure 1 ). In contrast, percentage motility was signi®cantly enhanced (P`0.05) in the pentoxifylline (3 mM)-treated sperm from normal donors as well as infertile patients when compared to Ham's and sildena®l after 3 hours (Figure 1 ). No signi®cant change in forward progression (grade assessment 1 ± 3) of spermatozoa from normal donors (grade 3) or infertile patients (grade 2) with varying doses of sildena®l (125, 250 and 750 ng) was observed when compared to Ham's control. However, motility grade was signi®cantly enhanced in infertile donors treated with pentoxifylline (grade 3) after 3 h compared to grade 2 sperm treated with varying doses of sildena®l or Ham's control. The motility grade of spermatozoa from healthy donors incubated in 750 ngaml of sildena®l was 3.5 AE 0.5 at 0 h and 3.0 AE 0.1 at 3 h, compared to 3.5 AE 0.5 motility grade at 0 h and 3.0 AE 0.
Effect of sildena®l on sperm viability
No signi®cant change in viability was observed at 0, l and 3 h after incubation of spermatozoa from normal donors with sildena®l (125, 250 and 750 ngaml) and pentoxifylline (3 mM) when compared to Ham's control (Figure 2A ). However, sperm from infertile patients incubated with pentoxifylline (3 mM) demonstrated an increase in viability when compared to sildena®l (125, 250 and 750 ngaml) and Ham's control ( Figure 2B ). Sperm viability was not signi®cantly different (P b 0.05) when sperm incubated with Ham's were compared to sperm incubated with sildena®l (125, 250 and 750 ngaml) at 0 h ( Figure 2B ). When sperm from infertile patients incubated with Ham's control, pentoxifylline (3 mM), and sildena®l (125, 250 and 750 ngaml) were compared after 1 h, viability was signi®cantly lower (P`0.05) in the 125 and 750 ngaml sildena®l groups when compared to the Ham's control and pentoxifylline groups ( Figure 2B) . After 3 h, sperm viability had signi®cantly decreased (P`0.05) in the Ham's control and sildena®l groups. When sperm from infertile patients incubated with Ham's control, pentoxifylline (3 mM) and sildena®l (125, 250 and 750 ngaml) were compared after 3 h, viability was signi®cantly lower (P`0.05) in the 125, 250 and 750 ngaml sildena®l and Ham's control groups when compared to the pentoxifylline (3 mM) group ( Figure  2B ).
Effect of sildena®l on membrane integrity
Sperm membrane integrity, assessed by HOST at 0 and 3 h, was not signi®cantly decreased (P`0.05) in Effects of sildena®l on sperm M Burger et al samples from normal healthy donors treated with Ham's, pentoxifylline (3 mM), and sildena®l (125, 250 and 750 ngaml; Figure 3 ). However, sperm membrane integrity in samples from infertile patients was signi®cantly decreased (P 0.05) when incubated with Ham's, pentoxifylline (3 mM), and sildena®l (125, 250 and 750 ngaml) after 0 and 3 h when compared to normal donors (Figure 3 ).
Sperm penetration assay (SPA)
Sildena®l and pentoxifylline-treated spermatozoa from both normal donors and infertile patients showed no signi®cant change in SPA from respective controls. The SPA for normal donor sperm samples (n 5) ranged from 5 to 16 sperm penetrations per ovum in the absence or presence of sildena®l. This is in comparison to 7 ± 22 sperm penetrations per ovum in sperm samples obtained from infertile patients in our study (n 5; data not shown).
Discussion
In this study, the effects of sildena®l on sperm from both normal and infertile men were evaluated. Sildena®l selectively inhibits the type-5 cGMPspeci®c PDE, which results in increased levels of intracellular cGMP. This cytosolic second messenger (cGMP), which is stimulated by nitric oxide, regulates many cellular functions, including intracellular calcium levels. Calcium has been implicated in sperm motion and function. 12, 13 Nitric oxide is known to adversely affect sperm motion and viability, probably due to its capacity as a free radical inducing direct oxidative damage to the sperm membrane. 14 This effect of NO is concentration-dependent, however, as at low doses it is found to improve or maintain sperm motility, which might be connected to its role as a cGMP stimulant. 7, 15 However, in the present study, neither sperm damage nor increased motility were observed, indicating that spermatozoa may lack the PDE type-5 phosphodiesterase isozyme. In a recent in vivo study where sildena®l was administered to normal subjects, no effect on human spermatozoa quality or function was observed. 16 An increased level of intracytosolic cAMP and cGMP has been linked to enhanced sperm motility and viability. 1, 17 This increase of cGMP may not be dependent upon PDE inhibition. There are reports that at least two different PDE isozymes, PDE1 and PDE4, are found in human sperm. 2 Sildena®l does not compete with the allosteric cGMP sites of PDE 5, but binds to special catalytic sites of PDE 5, thus inhibiting this enzyme. 18 PDE 5 has been found in the smooth muscles of the penile corpora cavernosa, however it may not be present in human spermatozoa. 5 The doses of sildena®l used to incubate the spermatozoa samples were chosen according to the pharmacokinetic characteristics of this PDE inhibitor. An orally administered dose of sildena®l is rapidly absorbed, with maximum plasma levels occurring approximately 1 h after administration. It is usually prescribed in doses of 50 and 100 mg, with mean peak bioavailability in the range of about 40%. The mean maximum plasma concentration level after an oral dose of 50 mg is 250 ngaml, and after an oral dose of 100 mg is 750 ngaml. 19 The selection of doses used in the present study was based upon these maximum plasma levels commonly achieved, which are suggested to be the highest possible The viability of sperm from infertile patients after incubation in sildena®l, 125 and 750 ngaml for 1 h, was signi®cantly lower when compared to pentoxifylline (3 mM) and Ham's. **(P`0.05) The viability of sperm from infertile patients incubated in all sildena®l doses studied and Ham's control was signi®cantly lower when compared to pentoxifylline after 3 h (3 mM) (n number of patients).
Effects of sildena®l on sperm M Burger et al concentrations to which spermatozoa could be exposed in testicular, prostatic and seminal vesicle tissue after oral administration of the common doses of sildena®l. It is possible that higher sildena®l concentrations over long periods of time may have deleterious or stimulatory effects on human spermatozoa. Further experiments are warranted to verify this theory. In order to compare a possible enhancement of sperm motion and function after incubation with sildena®l, an aliquot of the washed sperm sample was also exposed to pentoxifylline (3 nM), a nonspeci®c PDE inhibitor which increases intracellular cAMP speci®cally and enhances sperm motility. 17 In con®rmation of our previous results and similar reports from other laboratories, pentoxifylline signi®cantly enhanced sperm motion and membrane integrity. 2, 6, 17 This served as a positive control for all our evaluations in the present study.
The present study demonstrated no effect on any of the sperm parameters from a group of six healthy donors when various doses of sildena®l were added to the incubation medium for up to 3 h. When sildena®l was incubated in semen from men with clinical male infertility, there was no signi®cant effect found in respect to sperm motility. However, we observed a variable response in sperm viability in these samples when incubated with sildena®l for 1 and 2 h when compared to pentoxifylline. This decrease in sperm viability was due to the increase in viability that occurs when sperm are incubated with pentoxifylline. The sperm from infertile patients incubated with 125 ngaml of sildena®l exhibited a signi®cant decrease in sperm viability when compared to the HAM's control but this effect was not dose-dependent. The evaluation of sperm viabilityaintegrity by HOST suggests that spermatozoa from infertile patients have signi®cantly lower values compared to sperm from normal donors which were not affected by the presence of sildena®l. Further investigation of the effects of sildena®l on the sperm acrosome reaction is warranted as PDE inhibition in general has been shown to induce the acrosome reaction, which is probably a calcium-or cAMP-induced mechanism. 2 However, our SPA data suggests that there is neither a signi®cant enhancing nor deleterious effect of sildena®l on human spermatozoa in any of the doses employed. 11 Although the infertile patient samples used to perform the SPA demonstrated decreased motility, viability and membrane integrity, the ability to penetrate hamster ova was not diminished when compared to samples from normal donors. This con®rms the well-appreciated observation that SPA values can be within normal ranges, despite clinical infertility and decreased sperm motility, viability and membrane integrity parameters.
In summary, the results of the present investigation show that sildena®l at the dosages and time frames investigated (up to 750 ngaml and 3 h) had no signi®cant effect on motility, viability, membrane integrity or SPA of spermatozoa from fertile donors and infertile patients. Although these studies employ small sample size, our data indicates that sildena®l does not affect the sperm quality or function of both fertile and infertile men. Effects of sildena®l on sperm M Burger et al
